Clinical trials recruiting in Huizhou, China

Phase breakdown

Conditions recruiting in Huizhou, China

Recruiting trials in Huizhou, China

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
  NCT07483073 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
  NCT06064812 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
  NCT07483099 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
  NCT05837897 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06588855 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819891 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
  NCT07292714 · Phase: Phase 2 · Ages: 40 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  NCT06979336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
  NCT06471257 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
  NCT06975722 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female)
• A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
  NCT06419413 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female)
• ASPIrin in Reducing Events in Dialysis ( ASPIRED )
  NCT04381143 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
  NCT06754891 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
  NCT06932263 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
  NCT07307235 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female)
• Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
  NCT06304441 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
  NCT06296745 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
  NCT07415044 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
  NCT06141226 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Phase II Study of RC1416 Injection in COPD
  NCT07402551 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female)
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
  NCT06750289 · Phase: Phase 3 · Ages: 12 Years to 75 Years · Sex: All (male and female)
• Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
  NCT06462092 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
  NCT07265570 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT07222566 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
  NCT06829784 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
  NCT06758401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
  NCT07177339 · Phase: Phase 3 · Ages: 40 Years to 75 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Huizhou, China?

52 recruiting trials have at least one study site in Huizhou, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.